1. LaPlanta KL, Dhand A, Wright K. Lauterio M. Re-establishing the clinical utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine 2022;
54(1): 1686-1700.
2. Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics 2021; 13(2085): 1-30.
3. Moffa M, Brook I. Tetracyclines, Glycylcyclines and Chloramphenicol In: Bennet JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases.
9th edition Elsevier, Philadelphia 2020,p. 318-336.
4. Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother. 2016; 60(8): 4433–4441.
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States,
Canada, Latin America, Europe, and the western pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis 2001; 32(suppl 2): 114–132.
6. Sığ AK, Duran AÇ, Atik TK, Özen N, Irmak O, Yarar M. Distrubition of clinical Staphylococcus aureus isolates and antibiotic resistance profile: Three year data. J Contemp Med 2022; 12(6):
984-988.
7. Arıcı N, Aksaray S. Klinik örneklerden izole dilen Staphylococcus aureus suşlarının metisilin direncinin belirlenmesi ve antibiyotik duyarlılıklarının araştırılması. ANKEM Derg 2019; 33(2):
70-76.
8. Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species
complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis 2016; 85(3): 352-355.
9. Torre I, Alfano R, Borriello T et al. Environmental surveillance and in vitro activity of antimicrobial agents against Legionella pneumophila isolated from hospital water systems in Campania,
South Italy: a 5 year study. Env Res 2018; 164: 574-579.
10. Zhang C, Ouyang Q, Zhou X, Huang Y, Zeng Y, Deng L, et al. In vitro activity of tetracycline anologs against multi-drug resistant and extensive drug resistance clinical isolates of Mycobacte-
rium tuberculosis. Tuberculosis 2023; 140: 102336.
11. Yılmaz GR. Tetrasiklinden tigesikline. ANKEM Derg 2013; 27(Ek 2): 118-123.
12. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of
the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019, 200, e45-e67.
13. Ak K, Arabacı Ç. Resistance of Streptococcus pneumonaie strains isolated from clinical samples to various antibiotics. Dicle Med J 2020; 47(4): 779-786.
14. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A. et al.. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med 2019;380: 517–527
15. Bidell MR, Pai MAP, Lodise TP. Use of oral tetracyclines in the treatment of adult patients with community-acquired bacterial pneumoniae: A literature review on the often over-looked
antibiotics. Antibiotics 2020; 9(12): 905; https://doi.org/10.3390/antibiotics9120905
16. Khanna S. Do tetracyclines have the potential to reduce the risk of Clostridium difficile infection. Exp Rev Antiinfect Ther 2018 (16)3: 183-185.
17. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021; 70(4): 1-187.
18. Ahmadi MH. Global status of tetracycline resistance among clinical isolates of Vibrio cholerae ; a systematic review and meta-analysis. Antimicrob Resist Infect Control 2021; 10: 115.
19. Tan RK, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: Report from ithe CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med
Hyg 2011; 84(4): 517-531.
20. Tan K, Abanyie F. Travel associated infections and diseases: Malaria. CDC Yellow Book, 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria#prevent
21. Lago K, Telu K, Tribble D, Ganesan A, Kunz A, Geist C et al. Doxycycline malaria prophylaxis impact on risk of traveller’s diarrhea among international travellers. Am J Trop Med Hyg 2020;
103(5): 1864-1870.
22. Kantele A, Mero S, Laaveri T. Doxycycline as an antimalarial : Impact on travellers’ diarrhoea and doxycycline resistance among various stool bacteria: Prospective study and literature review.
Trav Med Infect Dis 2022; 49 https://doi.org/10.1016/j.tmaid.2022.102403
23. KLİMİK Derneği Kanıta Dayalı Bruselloz Tanı ve Tedavi Rehberi-2023. https://www.klimik.org.tr/wp-content/uploads/2023/04/Hasan.Selcuk.Ozger_.KLIMIK.Bruselloz.rehber.16.03.2023_
compressed.pdf
24. Lyme: Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero- Rosenfeld ME, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy
of Neurology, and American College of Rheumatology 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Am Acad Neurol 2021; 96(6): 262-273.
25. Lyme disease, CDC https://www.cdc.gov/lyme/index.html
26. MMWR Diagnosis and Management of Q Fever — United States, 2013 Recommendations from CDC and the Q Fever Working Group. 2013; 62(3): 1-32.
27. Leutkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023; 388:
1296-1306.
28. Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci 2010; 67: 419-431.
29. Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med 2016;6:a025387
30. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of acompounds with promising therapeutic properties: Review of the literature. Am J Physiol Cell Physiol
2010; 299: 539-548.
31. Burgos RM, Rodvold KA. Omadacycline: a novel aminomethylcycline. Infect Drug Resist 2019; 12: 1895-1915.
32. Markham A, Keam SJ. Omadacycline: First global approval. Drugs 2018; 78: 1931-1937.
33. Scott LJ. Eravacycline: A review in complicated intra-abdominal infections. Drugs 2019; 79: 315-324.
34. Heaney M, Mahoney MV, Gallagher JC. Eravacycline: The tetracyclines strike back. Ann Pharmacother 2019; 53(11): 1124-1135.
35. Deeks ED. Sarecycline: First global approval. Drugs 2019; 79: 325-329.
36. Zha L, Pan L, Guo J, French N, Viilanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: A systematic review and meta-analysis. Adv
Ther 2020; 37: 1049-1064.
37. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, etal. Tigecycline antibacterial activity, clinical effectiveness and mechanisms and epidemiology of resistance: narrative
view. Eur J Clin Microb Infect Dis 2022; 41: 1003-1022.
38. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et.al. Comparison of tigecycline with imipenem-cilastatin for the treatment of hospital acquired pneumoniae. Diagn
Microbiol Infect Dis 2010; 68(2): 140-151.
39. Grolman DC. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int J Infect Dis 2007; 11(S1): S7-S15.
40. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram- Negative
Infections. https://www.idsociety.org/practiceguideline/amr-guidance/
41. Korczak L, Majewski P, Iwaniuk D, Sacha P, Matulewicz M, Wieczorek P, et al. Molecular mechanisms of tigecycline resistance among Enterobacterales. Front Cell Infect Microbiol 2024; 14:
1289396.
42. Balbi HJ. Chloramphenicol: A review. Pediatr Rev 2004; 25(8): 284-288.
43. Raz NE, Lador A, Weissman YL, Elbaz M, Paul M, Leibovici L. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomi-
zed controlled trials. J Antimicrob Chemother 2015; 70: 979-996.
44. Nitzan O, Suponitzky U, Kennes Y, Chazan B, Raz R, Colodner R. Is chloramphenicol making a comeback? IMAJ 2010; 12: 371-374.